Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BridgeBio Oncology Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding BridgeBio Oncology Therapeutics, Inc.’s stock price such as:

• BridgeBio Oncology Therapeutics, Inc.’s current stock price and volume
• Why BridgeBio Oncology Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for BBOT from analysts
• BBOT’s stock price momentum as measured by its relative strength

About BridgeBio Oncology Therapeutics, Inc. (BBOT)

Before we jump into BridgeBio Oncology Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Want to learn more about BridgeBio Oncology Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BridgeBio Oncology Therapeutics, Inc..

BridgeBio Oncology Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, BridgeBio Oncology Therapeutics, Inc.’s stock price was $8.090.

BridgeBio Oncology Therapeutics, Inc. is down 4.82% from its previous closing price of $8.500.

During the last market session, BridgeBio Oncology Therapeutics, Inc.’s stock traded between $8.010 and $8.590. Currently, there are approximately 80.03 million shares outstanding for BridgeBio Oncology Therapeutics, Inc..

BridgeBio Oncology Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

BridgeBio Oncology Therapeutics, Inc. Stock Price History

BridgeBio Oncology Therapeutics, Inc.’s (BBOT) price is currently up 6.17% so far this month.

During the month of July, BridgeBio Oncology Therapeutics, Inc.’s stock price has reached a high of $9.460 and a low of $7.575.

Over the last year, BridgeBio Oncology Therapeutics, Inc. has hit prices as high as $14.870 and as low as $7.000. Year to date, BridgeBio Oncology Therapeutics, Inc.’s stock is down 35.38%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BridgeBio Oncology Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded BridgeBio Oncology Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate BridgeBio Oncology Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BridgeBio Oncology Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BridgeBio Oncology Therapeutics, Inc. (BBOT) by visiting AAII Stock Evaluator.

Relative Price Strength of BridgeBio Oncology Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, BridgeBio Oncology Therapeutics, Inc. has a weighted four-quarter relative price strength of -8.84%, which translates to a Momentum Score of 27 and is considered to be Weak.

Want to learn more about how BridgeBio Oncology Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BridgeBio Oncology Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, BridgeBio Oncology Therapeutics, Inc.’s stock price is $8.090, which is down 4.82% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BridgeBio Oncology Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.